This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have upgraded their ratings for several companies, including Haemonetics Corporation, Ciena Corporation, McCormick & Company, Klaviyo, and Darling Ingredients. These upgrades come with increased price targets, indicating a positive outlook for these stocks.
June 12, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Meta Marshall upgraded Ciena Corporation from Equal-Weight to Overweight, raising the price target from $53 to $55. Shares rose 0.2% to $45.92.
The upgrade to Overweight and a higher price target indicate a positive outlook for Ciena, likely resulting in a short-term price increase.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Citigroup analyst Thomas Palmer upgraded Darling Ingredients Inc. from Neutral to Buy with a price target of $48. Shares fell 1.5% to $37.34.
The upgrade to Buy and a significant price target increase to $48 suggest strong confidence in Darling Ingredients' future performance, likely leading to a positive short-term impact on the stock price despite the recent decline.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Needham analyst Mike Matson upgraded Haemonetics Corporation from Hold to Buy with a price target of $112. Shares closed at $83.41, down 2.8%.
The upgrade from Hold to Buy and a significant price target increase to $112 suggests strong confidence in Haemonetics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Barclays analyst Raimo Lenschow upgraded Klaviyo, Inc. from Equal-Weight to Overweight, boosting the price target from $25 to $29. Shares rose 0.1% to $22.58.
The upgrade to Overweight and a higher price target indicate a positive outlook for Klaviyo, likely resulting in a short-term price increase.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 100
POSITIVE IMPACT
Citigroup analyst Thomas Palmer upgraded McCormick & Company from Sell to Neutral, increasing the price target from $68 to $69. Shares rose 1.6% to $69.20.
The upgrade from Sell to Neutral and a slight increase in the price target suggest a more stable outlook for McCormick, likely leading to a modest positive impact on the stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100